Royal DSM’s venture investment arm, DSM Venturing, has made an equity investment in skin microbiome company S-Biomedic NV. This investment completes S-Biomedic’s latest Series A financing round.
 
S-Biomedic is a Belgium based life sciences company pioneering a new approach to cosmetic and therapeutic potential of the skin microbiome.
 
This investment underlines DSM’s interest in the skin microbiome, an area it has identified as having significant growth potential. DSM already holds a strong position in gut microbiome research and solutions with its Culturelle product range.
 
“With its long-established expertise in skin biology and in-depth knowledge in the field of epidermal science DSM is well placed to extend its research and innovation focus on the skin microbiome. We have already made encouraging discoveries about how skin actives in our existing product portfolio work on the skin and scalp microbiome. Through this investment, we hope to foster further innovation in the field” commented Rishabh Pande, vice president marketing and innovation personal care and aroma at DSM.